EQL Pharma AB (publ) (STO:EQL)

EQL Pharma AB Statistics

Total Valuation

EQL Pharma AB has a market cap or net worth of SEK 1.91 billion. The enterprise value is 2.28 billion.

Market Cap	1.91B
Enterprise Value	2.28B

Important Dates

The last earnings date was Tuesday, February 3, 2026.

Earnings Date	Feb 3, 2026
Ex-Dividend Date	n/a

Share Statistics

EQL Pharma AB has 29.53 million shares outstanding. The number of shares has increased by 0.22% in one year.

Current Share Class	29.53M
Shares Outstanding	29.53M
Shares Change (YoY)	+0.22%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	2.38%
Owned by Institutions (%)	1.59%
Float	21.72M

Valuation Ratios

The trailing PE ratio is 66.15 and the forward PE ratio is 34.75.

PE Ratio	66.15
Forward PE	34.75
PS Ratio	4.49
PB Ratio	7.09
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 26.14, with an EV/FCF ratio of -182.23.

EV / Earnings	77.64
EV / Sales	5.35
EV / EBITDA	26.14
EV / EBIT	34.23
EV / FCF	-182.23

Financial Position

The company has a current ratio of 2.16, with a Debt / Equity ratio of 1.62.

Current Ratio	2.16
Quick Ratio	1.03
Debt / Equity	1.62
Debt / EBITDA	5.02
Debt / FCF	-34.97
Interest Coverage	2.30

Financial Efficiency

Return on equity (ROE) is 12.28% and return on invested capital (ROIC) is 8.35%.

Return on Equity (ROE)	12.28%
Return on Assets (ROA)	6.53%
Return on Invested Capital (ROIC)	8.35%
Return on Capital Employed (ROCE)	10.41%
Weighted Average Cost of Capital (WACC)	6.26%
Revenue Per Employee	7.74M
Profits Per Employee	533,473
Employee Count	55
Asset Turnover	0.67
Inventory Turnover	1.39

Taxes

In the past 12 months, EQL Pharma AB has paid 7.66 million in taxes.

Income Tax	7.66M
Effective Tax Rate	20.70%

Stock Price Statistics

The stock price has decreased by -22.12% in the last 52 weeks. The beta is 0.41, so EQL Pharma AB's price volatility has been lower than the market average.

Beta (5Y)	0.41
52-Week Price Change	-22.12%
50-Day Moving Average	55.06
200-Day Moving Average	72.49
Relative Strength Index (RSI)	63.05
Average Volume (20 Days)	33,132

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, EQL Pharma AB had revenue of SEK 425.75 million and earned 29.34 million in profits. Earnings per share was 0.98.

Revenue	425.75M
Gross Profit	175.36M
Operating Income	66.55M
Pretax Income	37.00M
Net Income	29.34M
EBITDA	85.36M
EBIT	66.55M
Earnings Per Share (EPS)	0.98

Balance Sheet

The company has 72.67 million in cash and 437.08 million in debt, with a net cash position of -364.41 million or -12.34 per share.

Cash & Cash Equivalents	72.67M
Total Debt	437.08M
Net Cash	-364.41M
Net Cash Per Share	-12.34
Equity (Book Value)	269.78M
Book Value Per Share	9.14
Working Capital	202.36M

Cash Flow

In the last 12 months, operating cash flow was -2.36 million and capital expenditures -10.14 million, giving a free cash flow of -12.50 million.

Operating Cash Flow	-2.36M
Capital Expenditures	-10.14M
Free Cash Flow	-12.50M
FCF Per Share	-0.42

Margins

Gross margin is 41.19%, with operating and profit margins of 15.63% and 6.89%.

Gross Margin	41.19%
Operating Margin	15.63%
Pretax Margin	8.69%
Profit Margin	6.89%
EBITDA Margin	20.05%
EBIT Margin	15.63%
FCF Margin	n/a

Dividends & Yields

EQL Pharma AB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.22%
Shareholder Yield	-0.22%
Earnings Yield	1.53%
FCF Yield	-0.65%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	3